| DB ID | MyCo_5458 |
| Title | Diagnostic Performance of (1→3)-β-D-Glucan Alone and in Combination with Aspergillus PCR and Galactomannan in Serum of Pediatric Patients after Allogeneic Hematopoietic Stem Cell Transplantation |
| Year | 2021 |
| PMID | 33810069 |
| Fungal Diseases involved | Invasive aspergillosis |
| Associated Medical Condition | Pediatric Patients after Allogeneic Hematopoietic Stem Cell Transplantation |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | No ethical approval was necessary because BDG testing was performed retrospectively and no clinical management decisions were based on BDG results. |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Germany |
| Cohort | From April 2016 to March 2018 (24 months), 41 pediatric patients treated at the University Children’s Hospital Würzburg were screened twice weekly by GM and PCR-based diagnostic assays. All available patients with more than two serum samples and existence of frozen backup samples (n = 26) were selected for retrospective BDG analysis. Patients (12 males, median age of 11.5 years (range, 2 to 19 years); 14 females, median age of 8.5 years (range, 2 to 18 years)) were all eligible and in preparation for alloSCT. |
| Cohort No. | 41 |
| Age Group | Feb-19 |
| P Value | None |
| Sensitivity | 0.6 |
| Specificity | 0.95 |
| Positive Predictive Value | 0.75 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | (1→3)-beta-D-Glucan (BDG) is a fungal cell wall component released into patients’ blood during invasive fungal disease (IFD). BDG is not specific for Aspergillus infection, and could therefore be used as a broad spectrum fungal biomarker keeping in mind that it is not detectable in IFD caused by mucormycetes, Cryptococcus or Blastomyces dermatitidis. Confounding factors leading to false positivity include bacteremia and various intravenous medications. |
| Technique | PCR |
| Analysis Method | Aspergillus PCR |
| ELISA kits | Platelia™ Aspergillus Ag Kit (BioRad, Hercules, CA, USA) |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | GM-Platelia™ Aspergillus Ag ELISA,FDA approved Fungitell assay, Aspergillus PCR |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
